Amgen’s injectable Tepezza just cleared Phase 3 — and the timing is not a coincidence.
The company posted positive subcutaneous data for teprotumumab in thyroid eye disease this week, with Viridian Therapeutics pursuing the same indication. That’s the franchise on the line.
The original Tepezza is an IV infusion. Multiple clinic visits. Long chair times. Viridian has been making that case, arguing a cleaner delivery profile can crack a market where Amgen has faced no real competition yet.
A subcutaneous Tepezza changes the math. Prescribers already familiar with the drug, already seeing results, have one less reason to try something new. Converting an IV-dominant franchise to a self-injectable one is a classic defense move.
The race is to the FDA’s inbox. Whoever files first has the better claim to the convenience narrative, and that’s not a small thing in a disease where patients go through months of treatment.
No BLA submission timelines have been announced by either company.
— Sarah Chen